Kidney Cancer Association | Association Partnerships

Latest from Kidney Cancer Association


Promising Results of Cabozantinib/Nivolumab in Non-Clear Cell RCC Could Guide Future Research

March 11, 2022

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.